Sentinel Medical Technologies appears in FDA 510(k) records as the applicant behind TraumaGuard, a device regulated as a urological catheter and accessories under 21 CFR 876.5130, Class II, product codes EZL and PHU. The company's documented footprint in the linked filings is narrow: one linked record in the current collection, a traditional 510(k) with a substantially equivalent decision. The manufacturer's own published documentation describes the catheter's construction and intended measurements, while the FDA clearance letters establish the regulatory scope. The profile below separates what the filings state from what the company's website and instructions for use describe, and leaves ownership, headquarters and commercial status unstated where the records do not address them. [1][2][4][8]
The 2026 clearance and its stated scope
K260756 covers the TraumaGuard Intra-Abdominal Pressure-Sensing System (000-0221). The FDA record lists a receipt date of March 9, 2026 and a decision date of September 4, 2026, with decision code SESE and the description Substantially Equivalent. The submission was a traditional 510(k) reviewed by the Gastroenterology, Urology advisory committee, with a summary included and no third-party review. The clearance letter names regulation number 21 CFR 876.5130, regulation name Urological Catheter and accessories, Class II, and product codes EZL and PHU. [1][2]
The same letter identifies the applicant contact as Jackelyn Rodriguez, Quality Assurance Regulatory Affairs Director, at an address on North Laura Street in Jacksonville, Florida. That address appears in a filing, not as a verified corporate headquarters. The letter's intended-use language ties the device to monitoring of intra-abdominal pressure and core body temperature, with measured pressure described as an aid in diagnosis of intra-abdominal hypertension and abdominal compartment syndrome. [2][5]
The earlier 2024 filing
An earlier clearance, K240057, was issued April 17, 2024 for the TraumaGuard Intra-abdominal Pressure Sensing System, again under 21 CFR 876.5130 with product codes EZL and PHU. The letter is addressed to Sentinel Medical Technologies, LLC, care of the same Jacksonville contact and address, and records a device dated February 28, 2024 and received February 29, 2024. The FDA premarket notification page for K240057 lists the applicant as Sentinel Medical Technologies, LLC and the device classification as Catheter, Retention Type, Balloon. [8][9]
The two filings share a device family name and regulatory classification but carry different device names and K numbers, and the linked collection does not establish whether the 2026 submission replaced, amended or supplemented the 2024 clearance. The current collection holds one linked record, the 2026 traditional 510(k) with a substantially equivalent decision; that count describes the linked filings as of the snapshot and is not a measure of total company sales, total portfolio or safety performance. [1][8]
What the manufacturer's documentation describes
The published instructions for use describe TraumaGuard as a urine drainage catheter with continuous biometric monitoring of intra-abdominal pressure and core body temperature. It is described as a silicone catheter with polyurethane sensing balloons, a urine drainage lumen, an inflation channel and an integrated retention balloon positioned about five centimeters from the tip. The pack described in that document contains four catheters, model number 000-0221. [4]
The manufacturer's safety information page states an intended use for drainage of urine and continuous measurement of intra-abdominal pressure and core body temperature, with measured pressure usable as an aid in diagnosing intra-abdominal hypertension and abdominal compartment syndrome. The same page lists the model number 000-0221 and a basic UDI string. Company website pages describe the system as hands-free monitoring for critical care patients and reference a burn care application; those characterizations come from the manufacturer's own published pages. [5][6][7]
Identity and open questions
The applicant name appears as Sentinel Medical Technologies, in the 2026 FDA record and as Sentinel Medical Technologies, LLC in the 2024 letter and premarket notification page. The linked sources do not establish a parent company, brand owner or corporate structure beyond the applicant entity named in each filing. Statements about clinical performance on the manufacturer's pages are attributed to that publisher and are not independently verified in the FDA records reviewed here. [1][8][9]

